Alexandra Trkola

Summary

Publications

  1. pmc Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies
    Irene A Abela
    Institute of Medical Virology, University of Zurich, Zurich, Switzerland
    PLoS Pathog 8:e1002634. 2012
  2. pmc MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
    Claudia R Ruprecht
    Institute of Medical Virology, University Hospital Zurich, Switzerland
    J Exp Med 208:439-54. 2011
  3. pmc Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
    Peter Rusert
    Institute of Medical Virology, University Hospital Zurich University of Zurich, 8006 Zurich, Switzerland
    J Exp Med 208:1419-33. 2011
  4. pmc Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010
  5. pmc Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland
    PLoS Med 3:e441. 2006
  6. pmc Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
    Peter Rusert
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 79:8454-69. 2005
  7. ncbi request reprint Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Nat Med 11:615-22. 2005
  8. pmc In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:1591-9. 2008
  9. ncbi request reprint Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, CH 8091, Switzerland
    J Infect Dis 196:313-20. 2007
  10. pmc Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:3834-42. 2008

Collaborators

Detail Information

Publications38

  1. pmc Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies
    Irene A Abela
    Institute of Medical Virology, University of Zurich, Zurich, Switzerland
    PLoS Pathog 8:e1002634. 2012
    ..Thus providing a plausible explanation for how HIV maintains infectivity and rapidly escapes potent and broadly active CD4bs directed antibody responses in vivo...
  2. pmc MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
    Claudia R Ruprecht
    Institute of Medical Virology, University Hospital Zurich, Switzerland
    J Exp Med 208:439-54. 2011
    ....
  3. pmc Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
    Peter Rusert
    Institute of Medical Virology, University Hospital Zurich University of Zurich, 8006 Zurich, Switzerland
    J Exp Med 208:1419-33. 2011
    ..Knowledge on how the V1V2 barrier functions in the context of the trimer to mask conserved epitopes on gp120 may aid future vaccine design...
  4. pmc Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010
    ..These residues in HIV gp120 might affect in vivo HIV-1 fitness either at the level of Env function or influence susceptibility to adaptive or innate immune response...
  5. pmc Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland
    PLoS Med 3:e441. 2006
    ..To explore the possibility that antibody-mediated complement lysis contributes to viremia control in HIV-1 infection, we measured the activity of patient plasma in mediating complement lysis of autologous primary virus...
  6. pmc Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
    Peter Rusert
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 79:8454-69. 2005
    ..Activities of these MAbs correlated significantly with each other, suggesting that common features of the viral envelope modulate their potencies...
  7. ncbi request reprint Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Nat Med 11:615-22. 2005
    ....
  8. pmc In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:1591-9. 2008
    ..Equally, this raises hopes that a preventive vaccine could become effective at comparatively lower neutralizing antibody titers...
  9. ncbi request reprint Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, CH 8091, Switzerland
    J Infect Dis 196:313-20. 2007
    ....
  10. pmc Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:3834-42. 2008
    ..In summary, our data support the notion that the in vivo activities of 2G12, 2F5, and 4E10 are likely due to direct neutralization or Fc receptor-mediated mechanisms such as phagocytosis and antibody-dependent cellular cytotoxicity...
  11. doi request reprint HIV sensitivity to neutralization is determined by target and virus producer cell properties
    Axel M Mann
    Institute of Medical Virology, University of Zurich, Switzerland
    AIDS 23:1659-67. 2009
    ....
  12. pmc In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
    Amapola Manrique
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 81:8793-808. 2007
    ..This remarkable vulnerability of the virus to interference within the MPER calls for a further evaluation of the safety and efficacy of MPER-targeting therapeutic and vaccination strategies...
  13. pmc HIV rebounds from latently infected cells, rather than from continuing low-level replication
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:16725-30. 2008
    ..Furthermore, a prolonged delay in restoration of pretreatment viral diversity after treatment interruption demonstrates a surprisingly sustained evolutionary bottleneck induced by punctuated antiretroviral therapy...
  14. pmc CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics
    Andreas Schweizer
    Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland
    PLoS Pathog 4:e1000109. 2008
    ....
  15. pmc Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)
    Beda Joos
    University Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Antimicrob Agents Chemother 50:1773-9. 2006
    ..Further studies examining tissue concentrations to explain the differential in vivo activity of the anti-gp120 antibody compared with those of the two anti-gp41 antibodies are warranted...
  16. pmc Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions
    Beda Joos
    University Hospital Zurich, Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Virol 79:9026-37. 2005
    ....
  17. ncbi request reprint Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol
    Peter Rusert
    Division of Infectious Diseases, University Hospital Zurich, Switzerland
    Virology 326:113-29. 2004
    ..Measuring viral infectivity may thereby function as an additional, useful marker in monitoring disease progression and evaluating efficacy of antivirals in vivo...
  18. pmc Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    J Virol 77:13146-55. 2003
    ....
  19. ncbi request reprint Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Blood 104:1784-92. 2004
    ..In summary, measuring the kinetics of antibody responses provided a marker to validate the responsiveness and capacities of the immune system of HIV-1-infected individuals and reflected the patients' ability to decrease viral set points...
  20. pmc Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors
    Axel Mann
    Institute of Medical Virology, University of Zurich, Zurich, Switzerland
    J Virol 87:5868-81. 2013
    ..These data provide a proof of concept that the DARPin technology holds promise for the development of HIV entry inhibitors with a unique mechanism of action...
  21. doi request reprint HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia
    Huldrych F Gunthard
    Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Zurich, Switzerland
    Clin Infect Dis 48:e117-20. 2009
    ..This evidence supports a mechanism other than cross-neutralizing antibodies for the mild course of HIV-1 infection in this woman...
  22. ncbi request reprint Divergent effects of cell environment on HIV entry inhibitor activity
    Peter Rusert
    Institute of Medical Virology, University of Zurich, University Hospital Zurich, Switzerland
    AIDS 23:1319-27. 2009
    ..In the present study, we investigate the influence the target cell context bears on HIV entry inhibition...
  23. ncbi request reprint Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    Antivir Ther 8:97-104. 2003
    ..In contrast, expression of HIV-UsRNAPBMC increased during STI and consequently provides a more sensitive, albeit not absolute cellular marker of ongoing HIV-1 replication...
  24. pmc HIV-1 replication activates CD4+ T cells with specificities for persistent herpes viruses
    Anna Haas
    Institute of Microbiology, ETH Zurich, Zurich, Switzerland
    EMBO Mol Med 2:231-44. 2010
    ..We propose that a large proportion of activated T cells during untreated HIV infection may be specific for herpes viral antigens and identify a novel mechanism contributing to chronic immune activation in untreated HIV-1 infection...
  25. ncbi request reprint Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies
    Annette Oxenius
    Institute for Microbiology, Eidgenossische Technische Hochschule, Zurich, Switzerland
    J Infect Dis 190:713-21. 2004
    ..These findings demonstrate the temporal relationship between viral escape from CD8+ T cell activity, decrease in HIV-1-specific T cell frequencies, and loss of control of viral replication...
  26. pmc Estimating the stoichiometry of human immunodeficiency virus entry
    Carsten Magnus
    Integrative Biology, ETH Zurich, Zurich, Switzerland
    J Virol 83:1523-31. 2009
    ..Our study identifies parameters that need to be defined to render the estimation of the stoichiometry of HIV entry possible...
  27. doi request reprint Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design
    Tina Riedel
    Chemistry Department, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
    Chembiochem 12:2829-36. 2011
    ....
  28. doi request reprint Mathematical models: a key to understanding HIV envelope interactions?
    Carsten Magnus
    Institute of Medical Virology, University of Zurich, Switzerland Electronic address
    J Immunol Methods 398:1-18. 2013
    ....
  29. ncbi request reprint HIV-host interactions: vital to the virus and key to its inhibition
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    Curr Opin Microbiol 7:555-9. 2004
    ..Nevertheless, current knowledge on the molecular interactions between HIV and host-cell factors has substantially broadened our understanding of the viral life cycle and opened new investigative areas for drug intervention...
  30. ncbi request reprint RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement
    Branka Roscic-Mrkic
    Division of Infectious Diseases, Department of Medicine, University Hospital, Zurich, Switzerland
    Blood 102:1169-77. 2003
    ..Here we show that silencing of CD44 in HeLa-CD4 cells prevents the activation of p44/p42 MAPK and leads to a substantial reduction in HIV-1 infectivity enhancement by RANTES...
  31. ncbi request reprint Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts
    Marek Fischer
    Department of Medicine, University Hospital Zurich, Switzerland
    Antivir Ther 7:91-103. 2002
    ..As shown by limiting dilution analysis, HIV-1 infected cells with such a repressed viral transcription pattern were observed at high frequencies in PBMC from untreated patients...
  32. pmc Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells
    Claudia F Althaus
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Retrovirology 9:27. 2012
    ..Thus, we applied a novel, sequence targeted enrichment strategy to capture HIV-1 derived sncRNAs in HIV-1 infected primary CD4+ T-lymphocytes and macrophages that allows a greater than 100-fold enrichment of low abundant sncRNAs...
  33. doi request reprint HIV vaccines: an attainable goal?
    Lucy Reynell
    Institute of Medical Virology, University of Zurich, Switzerland
    Swiss Med Wkly 142:w13535. 2012
    ..In this review we explore the difficult task of eliciting protective immune responses to HIV and highlight the hurdles that vaccine design must still overcome...
  34. pmc Immune senescence: relative contributions of age and cytomegalovirus infection
    Andrea Mekker
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Zurich, Switzerland
    PLoS Pathog 8:e1002850. 2012
    ..In summary, our results directly demonstrate in a mouse model that latent CMV-infection impairs immunity in old age and propagates immune senescence...
  35. doi request reprint Peptidomimetic inhibitors targeting the CCR5-binding site on the human immunodeficiency virus type-1 gp120 glycoprotein complexed to CD4
    Markus Seitz
    Department of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich X, Switzerland
    Chem Commun (Camb) 46:7754-6. 2010
    ....
  36. ncbi request reprint HIV-host interactions: vital to the virus and key to its inhibition
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    Curr Opin Microbiol 7:407-11. 2004
    ..Nevertheless, current knowledge on the molecular interactions between HIV and host-cell factors has substantially broadened our understanding of the viral life cycle and opened new investigative areas for drug intervention...
  37. pmc Astrovirus infection in hospitalized infants with severe combined immunodeficiency after allogeneic hematopoietic stem cell transplantation
    Werner Wunderli
    Division of Clinical Virology, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e27483. 2011
    ..It illustrates that astrovirus has the potential to cause severe disseminated lethal infection in highly immunocompromised pediatric patients...
  38. pmc HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
    Alexandra Trkola
    Division of Infectious Diseases, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 99:395-400. 2002
    ..Instead, HIV-1 acquires the ability to use CCR5 despite the inhibitor, first by requiring lower levels of CCR5 for entry and then probably by using the drug-bound form of the receptor...